Kiora Current Deferred Revenue vs Cash Analysis
KPRX Stock | USD 3.31 0.11 3.22% |
Kiora Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiora Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiora Pharmaceuticals is a good investment. Please check the relationship between Kiora Pharmaceuticals Current Deferred Revenue and its Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.
Current Deferred Revenue vs Cash
Current Deferred Revenue vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiora Pharmaceuticals Current Deferred Revenue account and Cash. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Kiora Pharmaceuticals' Current Deferred Revenue and Cash is 0.49. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash in the same time period over historical financial statements of Kiora Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiora Pharmaceuticals' Current Deferred Revenue and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Kiora Pharmaceuticals are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Current Deferred Revenue i.e., Kiora Pharmaceuticals' Current Deferred Revenue and Cash go up and down completely randomly.
Correlation Coefficient | 0.49 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Cash
Cash refers to the most liquid asset of Kiora Pharmaceuticals, which is listed under current asset account on Kiora Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Kiora Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Kiora Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 94.8 K in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.02) in 2024.
Kiora Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Kiora Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kiora Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Short Long Term Debt Total | 83.9K | 362.1K | 209.4K | 105.8K | 106.9K | 101.5K | |
Other Current Liab | 1.1M | 1.3M | 1.2M | 2.1M | 1.3M | 1.3M | |
Total Current Liabilities | 1.4M | 1.8M | 1.6M | 3.3M | 1.6M | 3.2M | |
Total Stockholder Equity | 6.6M | 7.0M | 9.2M | 11.4M | 6.1M | 6.4M | |
Property Plant And Equipment Net | 16.8K | 30.6K | 283.4K | 172.2K | 115.0K | 76.8K | |
Net Debt | (3.7M) | (823.6K) | (7.6M) | (5.9M) | (2.3M) | (2.5M) | |
Retained Earnings | (100.2M) | (108.3M) | (124.7M) | (134.5M) | (147.0M) | (154.3M) | |
Accounts Payable | 210.3K | 434.8K | 160.6K | 1.0M | 206.3K | 195.9K | |
Cash | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Non Current Assets Total | 5.8M | 13.3M | 9.1M | 11.0M | 9.0M | 6.1M | |
Non Currrent Assets Other | 114.4K | 102.1K | 88.0K | 82.3K | 45.0K | 42.8K | |
Cash And Short Term Investments | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Net Receivables | 4.9K | 91.0K | 529.6K | 1.4M | 2.0M | 2.2M | |
Common Stock Shares Outstanding | 79.5K | 114.8K | 241.1K | 732.3K | 538.0K | 564.9K | |
Liabilities And Stockholders Equity | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Non Current Liabilities Total | 2.1M | 6.4M | 7.2M | 4.0M | 6.0M | 10.2M | |
Other Current Assets | 542.7K | 449.6K | 1.2M | 343.1K | 233.4K | 416.6K | |
Other Stockholder Equity | 106.7M | 116.8M | 135.4M | 146.0M | 153.2M | 93.4M | |
Total Liab | 3.5M | 8.2M | 8.8M | 7.3M | 7.6M | 12.5M | |
Total Current Assets | 4.3M | 1.8M | 9.0M | 7.7M | 4.7M | 5.6M | |
Accumulated Other Comprehensive Income | 139.5K | (802.0) | (86.4K) | (182.7K) | (182.8K) | (173.7K) | |
Short Term Debt | 83.9K | 260.6K | 237.7K | 211.6K | 94.1K | 89.4K | |
Common Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 101.9K | |
Intangible Assets | 4.1M | 9.7M | 8.7M | 10.7M | 8.8M | 7.9M | |
Other Liab | 1.5M | 2.1M | 6.1M | 7.1M | 8.2M | 8.6M | |
Net Tangible Assets | 7.2M | 4.9M | 3.3M | 9.1M | 10.4M | 10.9M | |
Capital Lease Obligations | 83.9K | 83.9K | 209.4K | 105.8K | 106.9K | 96.0K | |
Net Invested Capital | 6.6M | 7.3M | 9.2M | 11.4M | 6.1M | 7.5M | |
Non Current Liabilities Other | 1.7M | 5.3M | 6.5M | 3.3M | 5.1M | 3.8M | |
Net Working Capital | 2.9M | 37.8K | 7.4M | 4.4M | 3.1M | 2.5M | |
Property Plant Equipment | 43.5K | 16.8K | 30.6K | 283.4K | 325.9K | 342.2K | |
Capital Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 100.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.